

CURRICULUM VITAE

Amalia Vassou MD MSc PhD



Current Position : Consultant Haematologist

Hospital:	University Hospital Ioannina Hellas		
Department:	Hematology Department		
Address:	Leoforos Stavrou Niarxou		
Postal Code:	45500		
City:	Ioannina		
Country:	Greece		
Telephone Number:	+30 2651099898 / 625/ 859	Fax Number:	+302651099655
Mobile:			
e-mail address:	amalia.vassou@gmail.com		

ACADEMIC QUALIFICATIONS

Degree and Certification	Institution	Period
Degree of Medicine	University of Ioannina Greece	1984-1991
Certificate of Completion of Specialty Training in Hematology CCST in Haematology	Hellenic Ministry of Health	1993-1999
PhD in Haematology	University of Ioannina Greece	2006-2010
Master of Science MSc “Clinical Trials: Design and Conduct”	National and Kapodistrian University of Athens	2019-2021

PhD thesis is entitled : “ Immunophenotypic and cytogenetic study in chronic lymphocytic leukemia. Contribution to disease prognosis.”

MSc thesis is entitled: “A survey of the characteristics of the EORTC Investigator-Initiated trials in oncology during 2009-2019.”

CLINICAL EXPERIENCE

Position held	Institution	Date
General doctor	Health Center Thesprotiko Greece	5/1991-10/1992
Trainee in Internal medicine	General Hospital of Veria Greece	12/1992-12/1994
Trainee in Haematology	Papanicolaou Hospital Greece	2/1995 - 6/1999
Consultant Haematologist	University Hospital of Ioannina Greece	7/2000 - present

POST SPECIALTY TRAINING

1/2/2000- 1/6/2000 : Registrar in Bone Marrow Transplant Unit Glasgow Royal Infirmary, Glasgow UK.

1/3/2001-1/3/2002 : Honorary Associate Specialist in Haematology/BMT Glasgow Royal Infirmary, Glasgow UK.

MEMBERSHIP: Hellenic Haematology Association. Greek Myeloma Study Group, European Hematology Association, American Society of Hematology.

PUBLICATIONS

1. A revised international prognostic score system for Waldenström's macroglobulinemia.

Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsolis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, **Vassou A**, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA. *Leukemia*. 2019 Nov;33(11):2654-2661. doi: 10.1038/s41375-019-0431-y. Epub 2019 May 22. PMID: 31118465

2. Acquired Hemophilia in an Elderly Patient with Carcinoma of the Ampulla of Vater.

Mavroeidis L, **Vassou A**, Zarkavelis G, Papadaki A, Mouzaki I, Ntellas P, Gkoura S, Gazouli I, Pentheroudakis G. *Case Rep Oncol*. 2020 Jan 13;13(1):1-6. doi: 10.1159/000504338. eCollection 2020 Jan-Apr. PMID: 32110212

3. CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.

Papoudou-Bai A, Marinos L, **Vassou A**, Kapsali E, Kanavaros P. *Case Rep Dermatol Med*. 2019 Jan 16;2019:3730915. doi: 10.1155/2019/3730915. eCollection 2019. PMID: 30792929

4. Chronic myelogenous leukemia in ulcerative colitis.

Katsanos KH, Vagias I, Tsianos VE, **Vassou A**, Tsianos EV. *Ann Gastroenterol*. 2011;24(1):64. PMID: 24714265

5. Concurrent cutaneous localization of Langerhans cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma in a patient with a history of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Papoudou-Bai A, **Vassou A**, Marinos L, Papathanasiou K, Kapsali E, Kanavaros P. *J Cutan Pathol*. 2020 Feb;47(2):161-165. doi: 10.1111/cup.13571. Epub 2019 Aug 23. PMID: 31441945

6. Composite hairy cell leukemia and chronic lymphocytic leukemia.

Papoudou-Bai A, **Vassou A**, Vartholomatos G, Briasoulis E, Kanavaros P. *J BUON*. 2016 Jul-Aug;21(4):1027-1029. PMID: 27685932 No abstract available.

7. Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature.
Boussios S, Zerdes I, **Vassou A**, Bareta E, Seraj E, Papoudou-Bai A, Pavlidis N, Batistatou A, Pentheroudakis G. *Hematol Rep.* 2018 Apr 3;10(1):7070. doi: 10.4081/hr.2018.7070. eCollection 2018 Mar 2. PMID: 29721249
8. Imipenem-cilastatin induced pure white cell aplasia.
Kalambokis G, **Vassou A**, Bourantas K, Tsianos EV. *Scand J Infect Dis.* 2005;37(8):619-620. doi: 10.1080/00365540510040205. PMID: 16138439
9. Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials.
Mauri D, Zarkavelis G, Filis P, Tsali L, Zafeiri G, Papadaki A, **Vassou A**, Georgopoulos C, Pentheroudakis G. *ESMO Open.* 2018 Jun 23;3(4):e000343. doi: 10.1136/esmoopen-2018-000343. eCollection 2018. PMID: 30018809
10. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E, Gavriatopoulou M, Kyrtsolis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsigotis P, **Vassou A**, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA. *Blood.* 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420. PMID: 26359434
11. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature.
Kastrisiou M, Kostadima FL, Kefas A, Zarkavelis G, Kapodistrias N, Ntouvelis E, Petrakis D, Papadaki A, **Vassou A**, Pentheroudakis G. *ESMO Open.* 2017 Oct 5;2(4):e000217. doi: 10.1136/esmoopen-2017-000217. eCollection 2017. PMID: 29067215
12. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
Dimopoulos MA, Anagnostopoulos A, Kyrtsolis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, **Vassou A**, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G. *J Clin Oncol.* 2007 Aug 1;25(22):3344-9. doi: 10.1200/JCO.2007.10.9926. Epub 2007 Jun 18. PMID: 17577016
13. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.
Kastritis E, Kyrtsolis MC, Morel P, Gavriatopoulou M, Hadjiharissi E, Symeonidis AS, **Vassou A**, Repoussis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA. *Haematologica.* 2015 Nov;100(11):e446-9. doi: 10.3324/haematol.2015.124149. Epub 2015 Aug 20. PMID: 26294729
14. Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment.
Hatzimichael E, Lagos K, **Vassou A**, Gougopoulou D, Papoudou-Bai A, Briasoulis E. *Mol Clin Oncol.* 2016 Jul;5(1):23-26. doi: 10.3892/mco.2016.866. Epub 2016 Apr 20. PMID: 27330758
15. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, **Vassou A**, Tzouvara E, Bourantas KL. *Hematol J.* 2004;5(6):475-9. doi: 10.1038/sj.thj.6200550.
16. Non-secretory multiple myeloma with involvement of the hand as initial manifestation.
Benetatos L, Alymara V, Chaidos A, **Vassou A**, Bourantas KL. *Leuk Lymphoma.* 2006 Aug;47(8):1677-9. doi: 10.1080/10428190600612420. PMID: 16966284
17. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient.
Benetatos L, Hatzimichael E, **Vassou A**, Bourantas KL. *Leuk Res.* 2007 Jan;31(1):119-20. doi: 10.1016/j.leukres.2006.03.008. Epub 2006 Apr 18. PMID: 16620969
18. Large B-cell transformation of chronic lymphocytic leukemia presenting as a penile mass and skin lesion.
Vassou A, Bai M, Benetatos L, Tsili A, Bourantas K. *Hematol Oncol Stem Cell Ther.* 2008 Jul-Sep;1(3):199-200. doi: 10.1016/s1658-3876(08)50032-x. PMID: 20063554

19. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.

Kastritis E, Zervas K, Repoussis P, Michali E, Katodrytou E, Zomas A, Simeonidis A, Terpos E, Delimbassi S, **Vassou A**, Gika D, Dimopoulos MA; Greek Myeloma Study Group. Clin Lymphoma Myeloma. 2009 Mar;9(1):50-2. doi: 10.3816/CLM.2009.n.012.PMID: 19362972

20. Multifocal extramedullary plasmacytoma with paraproteinemia, pleural involvement and retroperitoneal lymphadenopathy: an uncommon pattern of relapse of solitary osseous plasmacytoma.

Vassou A, Alymara V, Agelis E, Stefanaki S, Bourantas KL. Ann Hematol. 2006 May;85(5):335-6. doi: 10.1007/s00277-006-0086-4. Epub 2006 Feb 22. PMID: 16496148

21. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MUC overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.

Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, Damala K, **Vassou A**, Vartholomatos G, Kolaitis N, Pavlidis N. Cancer. 2004 Oct 15;101(8):1767-75. doi: 10.1002/cncr.20581. PMID: 15386335

22. Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis.

Benetatos L, Chaidos A, Alymara V, **Vassou A**, Bourantas KL. Eur J Haematol. 2005 Mar;74(3):273-4. doi: 10.1111/j.1600-0609.2004.00386.x. PMID: 15693801

23. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.

Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E, Kyrtsionis MC, Delibasi S, **Vassou A**, Pouli A, Zervas K, Anagnostopoulos N, Maniatis A; Greek Myeloma Study Group. Haematologica. 2006 Feb;91(2):252-4. PMID: 16461313

24. Effectiveness of rituximab as prophylaxis in thrombotic thrombocytopenic purpura.

Benetatos L, **Vassou A**, Bourantas KL. Clin Lab Haematol. 2006 Aug;28(4):288-9. doi: 10.1111/j.1365-2257.2006.00794.x. PMID: 1689897

25. Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease.

Vassou A, Alymara V, Chaidos A, Bourantas KL. Int J Hematol. 2005 Jun;81(5):421-3. doi: 10.1532/ijh97.e0431. PMID: 16158824.

26. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.

Greek Myeloma Study Group Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, **Vassou A**, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsionis MC, Konstantopoulos K, Spyropoulou-Vlachou M, Terpos E, Dimopoulos MA. Leukemia. 2014 Oct;28(10):2075-9. doi: 10.1038/leu.2014.110. Epub 2014 Mar 18. PMID: 24637336.

27. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

Dimopoulos MA, Delimpasi S, Katodritou E, **Vassou A**, Kyrtsionis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E. Ann Oncol. 2014 Jan;25(1):195-200. doi: 10.1093/annonc/mdt483. PMID: 24356630.

28. Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.

Voulgaris E, Pentheroudakis G, **Vassou A**, Pavlidis N. Lung Cancer. 2009 May;64(2):247-9. doi:10.1016/j.lungcan.2008.10.027. Epub 2008 Dec 12. PMID: 19070399.

29. Malignancies in beta-thalassemia patients: a single-center experience and a concise review of the literature.

Benetatos L, Alymara V, **Vassou A**, Bourantas KL. Int J Lab Hematol. 2008 Apr;30(2):167-72. doi:10.1111/j.1751-553X.2007.00929.x. PMID: 18333849.

Date: 17 / 09 /2021